Introduction
The population-attributable fraction (PAF) for cancer-related infections in more highly developed countries has been estimated to be 7.4% [1] . In 2012, approximately 195,000 of 2,635,222 new cancer cases (excluding non-melanoma skin cancers) occurring in the European Union (EU) [2] are estimated to be infection-related [1] . Human papillomaviruses (HPVs), hepatitis B virus (HBV), hepatitis C virus (HCV), and Helicobacter pylori (H. pylori) account for approximately 95% of these cases [1] . Because of the immunosuppression induced by human immunodeficiency virus (HIV), this virus should be also considered a cause of infectionrelated cancers in the EU. Current available evidence has been reviewed here to recommendin the fourth edition of the European Code Against Cancer and related 'Questions and 2.2. HPV vaccines 2.2.1. Scientific justification of the European Code Against Cancer recommendation 2.2.1.1. Efficacy and safety of HPV vaccines. Two prophylactic vaccines against HPV are currently marketed internationally and in the EU/European Economic Area (EEA) (which as of July 2013 includes EU-28 and Iceland, Lichtenstein and Norway); these include the bivalent vaccine produced by GlaxoSmithKline (Cervarix 1 ), and the quadrivalent vaccine produced by Merck (Gardasil 1 ), both of which originally had a three-dose schedule for girls (see below).
The two vaccines are based on virus-like particles (VLPs) produced by expression in insect cells (bivalent vaccine) or yeast (quadrivalent vaccine) of the HPV L1 gene, encoding the main component of the viral capsid. These VLPs are not infectious but are highly antigenic: they produce a strong antibody response that prevents infection by neutralizing infectious virions in the mucosa at the time of contagion [19] . The bivalent vaccine includes HPV16 and 18 VLPs and is produced with a complex adjuvant system (ASO4) consisting of monophosphoryl lipid A and alum. The quadrivalent vaccine, produced with alum adjuvant, includes HPV16 and 18 VLPs and also HPV6 and 11 VLPs.
For the first time in 2009, the World Health Organization (WHO) recommended the introduction of HPV vaccination into national immunization programs, targeting 9-13-year-old girls (i.e. before the onset of sexual activity) with a three-dose regimen [20] . Evidence available up to September 2008 from the three main randomized controlled trials (RCTs) at that time (i.e. FUTURE 1 and FUTURE 2 for the quadrivalent vaccine; PATRICIA for the bivalent vaccine) and immunobridging studies were used to support this recommendation. Immunogenicity studies showing that antibody response to the two licensed vaccines is stronger in adolescent girls (aged 10-14 years) than in young adult women (aged 15-25 years) [21] [22] [23] permitted bridging of efficacy data to adolescent girls. Recently, WHO updated its HPV vaccines position paper [24] to recommend a two-dose regimen with increased flexibility in the interval between doses (see below).
The evidence on HPV vaccination was updated in the European Code Against Cancer using the methodology described in greater detail in this issue (see Minozzi et al., 2015) . The Medline, Embase, PsycINFO and Cochrane Library databases were searched to identify systematic reviews (SRs) on the efficacy and safety of HPV vaccines in women; two SRs were selected [25, 26] . Additional scientific publications identified by the experts were also included (as detailed below) to complete the evidence. Due to the relatively low number of RCTs on efficacy and safety of HPV vaccines in men, individual studies on this topic were directly searched using the Cochrane Central Register of Controlled Trials (CENTRAL), and six articles [27] [28] [29] [30] [31] [32] were selected from the publications retrieved.
In women, the totality of the evidence reviewed is in line with the WHO recommendation with regard to both efficacy and safety; both vaccines were shown to be safe, generally well tolerated, and almost 100% effective in preventing persistent cervical HPV16/ 18 infections and associated precancerous lesions -CIN2 or 3 (CIN2 +) and adenocarcinoma in situ (AIS)among young women (mean age of approximately 20-22 years) not previously infected at the time of vaccination [25, [33] [34] [35] [36] [37] . No results from longitudinal follow-up studies are yet available on the magnitude of the effects on cervical or other cancers.
The vaccines were also shown to prevent infections and CIN1+ in women >25 and 45 years [38] [39] [40] who are naïve to the vaccinerelated HPV types, but the frequency of CIN2/3 was much lower in this age group than among younger women.
In non-cervical sites, the quadrivalent vaccine has been shown to prevent the majority of vulvar and vaginal HPV infections and lesions associated with HPV16 and 18, as well as genital warts caused by HPV6 and 11, as reviewed recently [19] . The bivalent vaccine has been shown to prevent anal, oral and vulvar HPV16/ 18 infections in young women [41] [42] [43] .
Both vaccines also afford limited protection against nonvaccine HPV types phylogenetically related to HPV16 and 18. A 6-month cross-protection has been reported against HPV31 persistent infection for the quadrivalent vaccine and against HPV31, 33, 45 and 51 persistent infections for the bivalent vaccine among HPV-naïve women [25, 26, 35, 44, 45] . Efficacy against persistent infections with types 31 and 45 seemed to decrease in bivalent vaccine trials with increased follow-up [26] , suggesting a waning of cross-protection over time. The significance of early protection against these additional types is not clear and needs to be monitored over the long term.
Among young men (16-26 years of age) naïve to vaccine-related HPV types, the quadrivalent vaccine has been shown to prevent persistent anogenital infection with HPV vaccine types, external genital lesions including penile, perianal, or perineal intraepithelial lesions, including genital warts [28] . The quadrivalent vaccine has been demonstrated to prevent anal intraepithelial neoplasia among men who have sex with men [30] . The quadrivalent and bivalent HPV vaccines were highly immunogenic for all vaccine types [27, 31] . RCT results and immunobridging studies [22, 27, 31] strongly suggest that, as in women, it would be more effective to vaccinate young men before they become sexually active.
RCTs conducted essentially prior to vaccine licensure provide evidence of an excellent safety profile for both vaccines [27] [28] [29] (reviewed in [46] ). Pooled analysis of safety data from the quadrivalent vaccine RCTs [47] or the bivalent vaccine [48] showed no significant difference between the vaccinated and the control group in terms of occurrence of serious adverse events or deaths. Further data are also available from passive and active postlicensure safety surveillance of HPV vaccines. This is an important component of the overall safety assessment of vaccines, as rare or unexpected adverse events can be detected which may not have been evident in clinical trials due to their limited sample size.
Passive surveillance activities are designed to systematically collect post-vaccination adverse events [49, 50] . For HPV vaccines, the minor adverse events most commonly reported through passive surveillance are injection site reactions, headache and dizziness [46, 51, 52] . Moreover, while a variety of serious outcomes and deaths have been reported, none has been attributed to the vaccines [46] .
Active surveillance activities involve population-based postlicensure clinical studies [49] . Concerns have been raised that HPV vaccines might be associated with such adverse events as miscarriages, syncope, anaphylaxis, venous thromboembolism and autoimmune diseases such as multiple sclerosis, cerebral vasculitis, Guillain-Barré syndrome or chronic pain conditions, but these safety outcomes have been evaluated in population-based studies and, to date, no association between HPV vaccines and such conditions has been identified [46, 51] . These results have been corroborated by reviews of safety data conducted by a number ofrecognized advisory bodies such as the Institute of Medicine which reviewed data on quadrivalent vaccine safety in 2011 [53] , and the WHO Global Advisory Committee on Vaccine Safety (GACVS) which has repeatedly reviewed data on both HPV vaccines, most recently in March 2014 [54] . The GACVS Committee has remained reassured by the safety profile of the HPV vaccines, and noted the importance of continued surveillance and epidemiological investigation with an emphasis on the collection of high-quality data. Such data are essential for interpretation of any adverse events which may occur following HPV vaccination. As highlighted in their 2014 report, interpretation requires due diligence and great care; allegations of harm being raised on the basis on "anecdotal observations and reports in the absence of biological or epidemiological substantiation" may lead to unacceptable harm when "as a result, safe and effective vaccines cease to be used" [54] . As an example of such harm, the media coverage of adverse events of HPV vaccines in November 2013 in France raised concerns about HPV vaccine safety, and had a negative impact on vaccination coverage; the proportion of mothers who did not wish to vaccinate their girls increased significantly after November 2013: 23% in September-November versus 35% in December 2013 [55] .
2.2.1.2.
Duration of protection: long-term effect and effectiveness. The longest duration of efficacy of the vaccines reported to date is approximately 8-10 years for a three-dose vaccine schedule [56] . Studiesincluding linkage to cancer registriesare ongoing to monitor the population impact of HPV vaccination. Cross-sectional studies of women aged 18-24 years who received Pap screening in family planning clinics throughout Australia showed a 77% decrease in prevalence of HPV types targeted by the quadrivalent vaccine from the period before (2005) (2006) (2007) to the period after the vaccine was widely implemented (2009-2010) [57] . The impact of HPV vaccination on the incidence of genital warts has been reported also for Australia [58, 59] and recently for Sweden [60] , showing a dramatic reduction in the incidence of genital warts in the HPV-vaccinated cohorts. It will probably be possible to determine the attributable reduction in the incidence of cervical and other HPV-related cancers only after several decades.
HPV vaccination does not eliminate the need for effective cervical cancer screening in the HPV-vaccinated cohorts (Armaroli et al., 2015), mainly because the vaccines do not protect against all oncogenic HPV types. However, vaccination has the potential to greatly decrease the intensity, cost, and morbidity associated with screening, and in the future the impact on screening may be even greater; the FDA has in December 2014 approved the HPV9-valent vaccine (Merck, Gardasil 9), which is produced using the same technology and adjuvant as the quadrivalent vaccine and includes HPV16, 18, 6, 11, 31, 33, 45, 52 and 58 VLPs [61] . Sanofi Pasteur has recently (June 2015) received approval from the European Medicines Agency (EMA) for marketing Gardasil 9 in the EU [62] . This vaccine has the potential to prevent approximately 90% of cervical, vulvar, vaginal and anal cancers in women caused by the vaccine HPV types.
By specifically targeting young girls for vaccination before HPV infection, and women for screening at the age of risk of developing cervical cancers, these two strategies have the potential to yield a greater benefit when implemented together rather than separately; however, their implementation should be coordinated in a comprehensive cervical cancer prevention program [63] .
Number of doses.
A study nested in the Costa Rica vaccine trial was the first to suggest the efficacy of fewer than the recommended three doses of the bivalent HPV vaccine: at 4 years of follow-up, no significant difference in efficacy against HPV16/ 18 persistent infection was observed when one or two doses of vaccine were administered, compared to the recommended threedose protocol [64] . In addition, several studies have shown that the immunogenicity of two doses of both vaccines, particularly among girls aged 9-14 years and when the doses are separated by 6 months, is not inferior to that of three doses among women aged 15-25/26 years, for which vaccine efficacy has been proven [65, 66] . The Strategic Advisory Group of Experts (SAGE) on immunization for the WHO has recently reviewed the evidence related to HPV vaccination schedules for both bivalent and quadrivalent vaccines. Results from a systematic review comparing the effects of twodose and three-dose HPV vaccination [67] were the basis for the WHO's recommendation of a two-dose vaccination schedule with a 6-month interval for both the bivalent and the quadrivalent vaccines if administered before age 15. There is no maximum recommended interval between doses, but if the interval between doses is shorter than 5 months a third dose is recommended at least 6 months after the first dose. The WHO also recommends prioritizing vaccination of the primary target population of young girls 9-13 years of age (for full details of the WHO position see [24] [68, 69] . The age group targeted by these programs varies from one country to another, but it commonly includes 11-13-year-old girls [68, 69] . Currently available data on three-dose HPV vaccination coverage in the EU indicate that coverage varies widely between countries and is rarely optimal; for example, coverage is low in Luxembourg (17%) and France (29%), medium in Italy (66%) and in the Netherlands (56%), and high in some countries such as the United Kingdom (80%) and Portugal (81%) [68] . Variance in coverage across the EU can be explained by different vaccine implementation policies and/or different reporting systems [69, 70] . Modelling suggests that additional implementation of catch-up vaccination for girls older than the primary target population may not enhance the long-term population effectiveness of vaccination against HPV16/ 18 infection. It may, however, shorten the period within which population effectiveness is reached by 2-5 years [71] . Of the 21 EU countries mentioned above, 11 (Belgium, Denmark, Finland, France, Italy, Luxembourg, the Netherlands, Portugal, Romania, Sweden and the United Kingdom) have also introduced catch-up programs. In several of these 11 countries, catch-up is offered to girls and women aged around 14-18 years who have not previously been vaccinated [68] .
The EMA has also granted marketing authorizations for Cervarix 1 and Gardasil 1 in the EU/EEA for a two-dose schedule administered by injection at a 6-month interval for girls aged 9-14 and 9-13 years respectively. If the respective vaccines are administered at an older age, the three-dose schedule should be used (for full details see [72, 73] ). Some countries, such as France and the UK, have already implemented a two-dose HPV vaccination policy. With the exception of Austria [74] , vaccinating midadult women (>26 years) is not routinely practiced in the national immunization programs; the cost-benefit ratio in this age range is reduced, in part because of the lower incidence of lesions among women infected by HPV later in life and the lower risk of progression of these lesions [75, 76] .
Based on results from RCTs and immunobridging studies, the national advisory committees on immunization in Australia [77] , Canada [78] and the US [79] have recommended including vaccination of young men in routine vaccination schedules. Except in Austria [74] , vaccination of boys is not currently offered in any public health vaccination program in the EU, as it has not been shown to be cost-effective because of the much lower burden of HPV-related cancers in men compared to women [80] . It is worthy of note, however, that modelling studies suggest that vaccination of boys might impact on cervical cancer burden by reducing HPV circulation in women, especially if high vaccine coverage is not achieved in girls [71] . However, HPV models are being reassessed at the moment in some EU countries to take into account new assumptions: i.e. the new two-dose vaccination schedule and price reduction of HPV vaccines. Some EU countries may include adolescent males and/or men in their current HPV vaccination programs in a near future.
Key points for the general public, healthcare providers and health policy makers
Based on the above evidence, the European Code Against Cancer recommends (to parents): "Ensure your children take part in vaccination programs for human papillomavirus (HPV) (for girls)" (Box 1, no.11).
In the questions and answers (Q&As) dealing with vaccination and infections on the European Code Against Cancer website [81] , the Working Group on Infections and Vaccination in the European Code Against Cancer project provides additional information that would be of particular relevance for parents, boys and girls, and young women interested in learning more about what they could do to lower the risk of cancer from HPV infection. Key messages include:
WHO recommends HPV vaccination for girls aged 9-13. This is because sexual activity usually begins at later ages, and most girls (9-13 years old) are therefore unlikely to have already been infected. HPV vaccination is highly effective in boys but is currently offered in only one public health program in the European Union. At the moment, parents can choose to have their adolescent sons vaccinated at their own expense in consultation with their doctor or healthcare provider. The current vaccines are highly effective in preventing infections with HPV types 16 and 18, the types that cause most cervical and anal cancers, but they do not prevent infection with all the types of HPV that may cause cancer. It is very important to remember that vaccination will profoundly diminish screening intensity but vaccinated women will still need to participate in cervical cancer screening.
Hepatitis B and hepatitis C viruses

Role in cancer
HBV and HCV target the liver and replicate in hepatocytes. They have been classified by the IARC Monographs Program as Group 1 human carcinogens [3] , and chronic HBV and/or HCV infection are the most important causes of hepatocellular carcinoma (HCC) worldwide with an estimated PAF of 77% [82] [83] [84] . People who become chronically infected with HBV and/or HCV (also known as carriers) are at higher risk of developing chronic liver disease, progressing from chronic hepatitis to fibrosis, cirrhosis, and finally HCC. Hepatitis B or C carriers generally have no noticeable symptoms until the liver has been significantly damaged. Cirrhosis can be considered a pre-cancerous stage, being found in 80-90% of patients with HCC [85] . Chronic HCV infection is also a risk factor for B-cell non-Hodgkin lymphoma (NHL) [3] . Direct HCV infection of B cells may be involved in this oncogenic process as peripheralblood B cells from HCV carriers have been shown to be infected with HCV [86] . However, HCV-associated NHL is rare, with an estimated PAF of 8% worldwide [82] .
HCC represents approximately 80-85% of primary liver cancers (PLCs) globally. PLC, roughly equivalent to rates of HCC, is predominant in men, being the fifth most common cancer in that gender (554,000 cases in 2012, 7.5% of total cancer cases worldwide) and the ninth most common in women (228,000 cases in 2012, 3.4% of total cases) [18] . On account of high lethality, HCC is the second most common cause of death from cancer worldwide (746,000 deaths in 2012, 9.1% of total deaths) [18] . Most of the burden of HCC is confined to developing countries; in 2012, 83% of new cases occurred in less developed regions. The regions of high incidence are Eastern and South-Eastern Asia (ASIR of 31.9/ Box 1. European Code Against Cancer.
12 ways to reduce your cancer risk 1. Do not smoke. Do not use any form of tobacco. 2.Make your home smoke free. Support smoke-free policies in your workplace. 3. Take action to be a healthy body weight. 4.Be physically active in everyday life. Limit the time you spend sitting.
Have a healthy diet:
Eat plenty of whole grains, pulses, vegetables and fruits. Limit high-calorie foods (foods high in sugar or fat) and avoid sugary drinks. Avoid processed meat; limit red meat and foods high in salt. 6.If you drink alcohol of any type, limit your intake. Not drinking alcohol is better for cancer prevention. 7.Avoid too much sun, especially for children. Use sun protection. Do not use sunbeds. 8.In the workplace, protect yourself against cancercausing substances by following health and safety instructions. 9.Find out if you are exposed to radiation from naturally high radon levels in your home. Take action to reduce high radon levels. 10. For women:
Breastfeeding reduces the mother's cancer risk. If you can, breastfeed your baby. Hormone replacement therapy (HRT) increases the risk of certain cancers. Limit use of HRT. 11. Ensure your children take part in vaccination programmes for: Hepatitis B (for newborns) Human papillomavirus (HPV) (for girls).
12. Take part in organized cancer screening programmes for: Bowel cancer (men and women) Breast cancer (women) Cervical cancer (women).
The European Code Against Cancer focuses on actions that individual citizens can take to help prevent cancer. Successful cancer prevention requires these individual actions to be supported by governmental policies and actions.
100,000 and 22.2/100,000, respectively) for men, and Eastern Asia and Western Africa (10.2 and 8.1, respectively) for women [18] . In the EU, by contrast, estimated incidence rates in men are low in the North (AISR of 2.4 and 4.6/100000, respectively, in the Netherlands and the UK) and intermediate in the South (Italy: 11; Portugal: 8.6; Spain: 9.9); some EU countries in the West and Eastsuch as France (11.3), Luxembourg (10.3) and Romania (9.2)also have intermediate rates ( Fig. 2 ) [18] . For women in the EU, the estimated ASIR ranges from 0.9 in the Netherlands to 3.6 in Italy [18] . Given the very poor prognosis of liver cancer, the geographical patterns of HCC incidence and mortality are quite similar [18] . Worldwide, the relative contributions of the major risk factors for HCCi.e. HBV and/or HCV chronic infection, consumption of aflatoxin-contaminated maize and groundnuts, and heavy alcohol consumptionvary by geographic region [83, 84] . Alcohol-associated liver cirrhosis (Scoccianti et al., 2015) is the most important risk factor for HCC in populations with low prevalence of HBV and HCV, as in the United States and Northern Europe [84, 87] . Aflatoxin exposure is a major risk factor in East and Southeast Asia and in sub-Saharan Africa, where regulatory control is weak [84] . In areas where chronic HBV or HCV infection endemicity is highhepatitis B surface antigen (HBsAg) prevalence 8% and anti-HCV >3.5% respectivelychronic HBV and/or HCV infection is a major risk factor for HCC [83] . The prevalence of chronic HBV infection is highest (HBsAG prevalence 8%) in Southeast Asia, China and sub-Saharan Africa and is also high in the southern parts of Eastern and Central Europe. Prevalence of chronic HCV infection is highest (anti-HCV 10%) in Pakistan, Egypt, and Mongolia, and is also high in some parts of China, Italy and Japan [84] .
In Europe, as observed worldwide, when comparing one geographic region to another, the contribution of chronic HBV/ HCV infection to the etiology of HCC varies between countries [88] . This variation is linked to the prevalence of chronic HBV/HCV infection, which varies widely between the countries in the European Union/European Free Trade Association (EU/EFTA) (as of July 2013: EU-28 and Iceland, Lichtenstein, Norway and Switzeland) [89] . Some countries, such as the Northern countries and the UK, can be considered at low risk for chronic HCV or/and HBV infection (estimated prevalences <1%) and at lower risk for infection-related HCC (Fig. 3) [88, 89] . For example, in Sweden about 15% of HCC cases are anti-HCV + and 3% are HBsAg + , while 82% are negative for both viruses. In Belgium and the UK about 25% are anti-HCV + and 20% are HBsAg + , while 45% are negative and 10% positive for both viruses [88, 89] . High-risk countries for chronic HBV infection are Greece (estimated prevalence 2.1%) and Romania (5.6%); in Greece about 56% of HCCs are HBsAg + and 16% are anti-HCV + , while 25% are negative and 3% positive for both viruses (Fig. 3 ) [88, 89] . High-risk countries for chronic HCV infection are South Italy (i.e. Sicily: 10.4%) and Romania (3.5%) ( Fig. 3 ) [88, 89] .
In the EU/EFTA region, about 4.5 million (HBV) and 5.5 million (HCV) adults are carriers [90] . These figures are likely underestimates; most hepatitis B or hepatitis C carriers are currently undiagnosed as chronic infection is usually asymptomatic until the late stages of liver damage. Moreover, people at high risk of being carriers, such as migrant groups from endemic countries and elderly people, are generally under-represented in the statistics. Reported data suggest that the prevalence of chronic HBV and/or HCV infections is higher in migrants from endemic countries than in the general population in the EU/EFTA [91] . In some Southern European countries like Italy, Spain and Portugal, the burden of 
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chronic liver disease related to hepatitis is increasing due to the ageing unvaccinated population (hepatitis B) and to injecting drug use (hepatitis C) [92] .
Hepatitis B virus
HBV is a DNA virus transmitted by exposure to infected blood and other body fluids, including semen and vaginal fluids. Around the time of birth, HBV is transmitted to babies by carrier mothers, and this is the main route of transmission in highly endemic regions. During childhood, transmission can occur between children living in close proximity, although the exact route is unclear. In adult life, the virus can spread through sexual contact or by use of contaminated needles. The age of infection is critically important in determining whether the infection can become chronic [84] ; HBV-infected newborns have an 80-90% probability of developing chronic infection; children infected in the first 5 years of life have a 20-50% probability of becoming carriers, while those infected in adult life have a probability of <10% of developing chronic infection. Conversely, the risk of developing acute hepatitis, ranging from no symptoms at all to severe illness (fever, jaundice and lethargy), is approximately one third in adult infections, but rare in children [84] .
Chronic infection is characterized by serum persistence (>6 months) of HBsAg. The risk of progression to liver disease is associated with active HBV replication, determined by tests for HBeAg and levels of HBV DNA [85] . There are various mechanisms by which HBV may promote carcinogenesis: (1) integration of HBV DNA into the host genome that alters the function of endogenous genes or induces chromosomal instability; (2) accumulation of genetic damage due to hepatic inflammation mediated by virusspecific T cells; and (3) induction of oxidative stress by expression of viral proteins HBx and HBs [93] .
Hepatitis C virus
HCV is an RNA virus with a highly variable genome. The distribution of HCV genotypes and sub-genotypes depends on the geographic region, and in Europe HCV1b is the main one [94] . HCV infection occurs mainly from contaminated blood or blood products. Before the 1990s, when widespread screening of the blood supply for HCV contamination began in developed countries, hepatitis C was commonly spread through blood transfusions and blood products. The risk of HCV transmission through donated blood is now very small in Europe and most developed countries, and most new infections with HCV occur by sharing needles or other equipment to inject drugs. Diagnostic procedures and treatments in healthcare facilities with inadequate infection control practices may also be a source of infection. This is the reason why hepatitis C epidemics can be concentrated in certain high-risk populations, for example among people who inject drugs and/or in general populations in certain areas. More rarely, HCV can also be acquired from sexual and household contacts [84] . HCV infection can be both acute and chronic. Unlike HBV, the risk of chronic infection with HCV does not decrease when infection occurs in adults. About 15% of those initially infected will develop acute hepatitis which is generally asymptomatic, and spontaneously clear the virus. The remaining 85% will become carriers [95] . Chronic infection is characterized by serum persistence (>6 months) of HCV RNA and HCV antibodies [96] . Approximately 20% of HCV carriers will develop HCC by the age of 75 years [97] . There is no vaccine available against HCV infection. Hepatitis B vaccines are composed of highly purified preparations of HBsAg. The first vaccines, available in 1982, were plasma-derived. Since 1986, these vaccines have been replaced by recombinant hepatitis B vaccine, which is obtained by expressing HBsAg in yeast or mammalian cells. Aluminum phosphate or aluminum hydroxide is used as an adjuvant. Hepatitis B vaccine is available as monovalent formulations or in fixed combination with other vaccines, including diphtheria-tetanus-pertussis (DTP), Haemophilus influenzae type b, hepatitis A, and inactivated polio.
Since 1997, WHO has recommended hepatitis B vaccination for all newborns, and the last updated position paper was published in 2009 [98] . The WHO recommended that all infants receive the hepatitis B vaccine (monovalent) as soon as possible after birth, preferably within 24 h, independently of whether the country has high, medium or low endemicity; two or three additional monovalent or combined vaccine dosesat 1 and 6 months of age in most countriesare given in addition to the birth dose to complete immunization.
The evidence on efficacy and safety of HBV vaccination was updated with a systematic search of the Medline, Embase, PsycINFO and Cochrane Library databases up to January 2013; two SRs [99, 100] were selected based on the European Code Against Cancer methodology. Neither of these reviews reported chronic hepatitis B, liver cirrhosis or HCC incidence or mortality outcomes but reported either anti-HB level [99] or occurrence of hepatitis B infection [100] . Ortqvist's SR [99] showed efficacy, but no meta-analysis was performed. Mathew's SR [100] showed contradictory results on efficacy depending on the method used to perform data analysis. The evidence available since the last WHO position paper is therefore summarized below using individual studies.
Effectiveness studies have been performed in highly HBV endemic countries or regions with high rates of HCC. Surveys on seroprevalence of HBsAg in children carried out before and after introduction of immunization programs show a significant reduction in the rate of chronic infection among immunized children. In China, where the immunization program was introduced in 1992, the prevalence of HBsAg positivity in children younger than 5 years decreased from 9.7% in 1992 to 1.0% in 2006 [101] . In Taiwan, since implementation of vaccination in 1984, seroprevalence in children decreased from 10% in 1984 to 0.9% in 2009 [102] . Comparison of vaccinated birth cohorts with unvaccinated ones in studies with 25-30 years of follow-up time have shown the effectiveness of hepatitis B immunization in lowering mortality from fulminant hepatitis and incidence of HCC in Taiwan [103] , Qidong City (China) [104] , Japan [105] , and Alaska [106] . The studies' results are summarized below.
In Taiwan, the birth cohort born in 1981-1984, which received HBV vaccines at preschool ages instead of early infancy, had significantly lower HCC mortality and incidence than those born in 1977-1980 (RR 0.70, 95%CI 0.59-0.83 of HCC mortality; RR 0.73, 95%CI 0.63-0.85 of HCC incidence) [103] .
In Qidong City, China, a controlled neonatal HBV vaccination trial began in 1983 and ended in November 1990. After the end of the trial, vaccination of newborns continued without interruption. Compared with 1980-1983, the age-specific liver cancer incidence rates in 2005-2008 significantly decreased 1.9-fold at ages 0-19, 14-fold at ages 20-24, 9-fold at ages 25-29, 4-fold at ages 30-34, 1.5-fold at ages 35-39, 1.2-fold at ages 40-44 and 1.4-fold at ages 45-49, but increased at older ages. The reduction at ages below 25 reflect the combined effects of interventions to reduce aflatoxin exposure and neonatal HBV vaccination [104] .
A nationwide prevention program utilizing immunoprophylaxis for high-risk newborn babies against maternal HBV transmission was introduced in Japan in January 1986. The number of patients with HBV-positive HCC and the ratio of HBV-positive HCC to hepatoblastoma decreased over the study period. There was a significant decrease in HBV-positive HCC during the last study periods (2001-2008) compared with HBV-negative HCC (P < 0.001) [105] .
A universal newborn immunization with hepatitis B vaccine was initiated in 1984 among Alaskan native people; the incidence of HCC in persons below 20 years of age decreased from 3/100,000 in 1984-1988 to zero in 1995-1999, and no cases have occurred since 1999 (test for trend overall, P < 0.001) [106] .
Only two RCTs initiated during the 1980s examine HCC as an outcome. They were conducted in areas where the high incidence of liver cancer was attributable to endemic HBV infection, but also to dietary exposure to aflatoxin. The Gambian Hepatitis Intervention Study (GHIS) was conducted from 1986 to 1990 in Gambia (Africa) [107] ; 24 years after vaccination, vaccine efficacy against chronic infection with hepatitis B virus was 95.1% (95% CI 91.5-97.1%) [108] . The latest estimates [109] indicate that the evaluation of the protective efficacy of HBV vaccine against HCC should be measurable from 2017. The Qidong Hepatitis B Intervention Study (QHBIS), an RCT of neonatal HBV vaccination, was conducted between 1983 and 1990 in Qidong County (China) [110] . This population-based, cluster randomized, controlled trial included 39,292 newborns who were randomly assigned to the vaccination group in which 38,366 participants completed the HBV vaccination series and 34,441 newborns who were randomly assigned to the control group in which the participants received neither a vaccine nor a placebo. However, 23,368 (67.8%) participants in the control group received catch-up vaccination at age 10-14 years. At 30-year follow-up, the incidence rate of primary liver cancer (PLC) and the mortality rates of infant fulminant hepatitis were significantly lower in the vaccination group than in the control group, with a risk reduction estimated to be 84% (95% CI 23-97%) and 60% (95% CI 34-86%) respectively [111] . The estimated efficacy of catch-up vaccination on HBsAg seroprevalence in early adulthood was substantially weaker than that of the neonatal vaccination. Limitations of the study results include the small number of individuals with PLC, the large number of participants lost to follow-up, and the large proportion of participants who did not provide serum samples at follow-up.
Since its availability in 1982, more than 1 billion doses of HBV vaccine have been used worldwide; so far no serious safety concerns regarding the HBV vaccines have been reported by any national or international (i.e. Global Alliance for Vaccines and Immunization, GAVI) surveillance system authority. No safety concern was highlighted either through exhaustive review of scientific evidence such as the one published in 2013 by the Institute of Medicine in the USA [112] .
In the EU, only four countries (Denmark, Finland, Sweden and the UK) have not introduced immunization against hepatitis B into their childhood immunization programs on account of the historically low prevalence of HBV infection in the general population. These countries opted instead for systematic highcoverage surveillance of pregnant women to identify carrier mothers, and administration of HBV vaccination only to newborns whose mother was infected. A survey of hepatitis B immunization programs was performed in 2008-2009 in 25 EU members [113] . Based on this survey, of the 20 countries with a childhood immunization program, 18 countries had the first hepatitis B vaccine dose scheduled at birth or 2-3 months after birth, and two countries vaccinated only schoolchildren. Of those 18 countries, 11 provided catch-up programs for older children or teenagers [113] .
3.2.1.2. Key points for the general public, healthcare providers and health policy makers..
Based on the above evidence, the European Code Against Cancer recommends (to parents): "Ensure your children take part in vaccination programs for hepatitis B (for newborns)" (Box 1, no.11).
In the Q&A section [81] , the Working Group on Infections and Vaccination also provided additional information that would be of particular relevance for parents interested in learning more about what they could do to lower the risk of liver cancer from hepatitis B infection (see also Section 3.2.2.3). A point considered by the Working Group to be particularly relevant is:
In a few EU countries (the United Kingdom and some Nordic countries) vaccination against hepatitis B is offered only to highrisk newborns (i.e. newborns of mothers who are HBV-positive). However, parents living in one of these countries may wish to consider having their children vaccinated at their own expense in consultation with their doctor or other healthcare provider.
The "test and treat" intervention
Because the disease is often asymptomatic and left untreated, people with chronic HBV and/or HCV infection remain infectious to others and are themselves at risk of serious liver disease such as liver cirrhosis or HCC. Various drugs for treatment of chronic HBV or HCV infection have received marketing authorization approval. Efficacy and safety of these drugs have been reviewed recently by a number of recognized advisory bodies to produce the following evidence-based guidelines or recommendations: WHO: guidelines for the screening, care and treatment of people with hepatitis C infection (2014) [114] ; National Institute for Health and Care Excellence (NICE): Hepatitis B and C testing: people at risk of infection (2012) [115] ; NICE: hepatitis B (chronic) diagnosis and management (2013) [116] ; European Association for the Study of the Liver (EASL): management of chronic hepatitis B infection (2012) [117] ; EASL: recommendations on treatment of hepatitis C (2014) [118] ; US Preventive Services Task Force (USPSTF): screening for hepatitis B virus infection in non-pregnant adolescents and adults (2014) [119] .
In summary, these guidelines recommend (1) to offer HBV and HCV serology testing to individuals from high-risk groups ( Table 1) ; (2) to assess carriers of HBV and HCV for antiviral treatment (i.e., selection of antiviral drugs to be used, duration of treatment, and subsequent monitoring of patients, genotyping being recommended only for chronic HCV infection); and (3) to offer adequate treatment to individuals with evidence of active infection or liver damage. NICE, EASL, and WHO guidelines also provide detailed recommendations and guidance to health professionals regarding protocols for treatment of carriers, taking into account patient assessment (e.g., severity of liver disease; previous treatment failure, and genotyping for chronic HCV infection). The NICE recommendations also take into account evidence of costeffectiveness. A summary of the evidence regarding efficacy and safety of the main currently available drugs that are described in the above guidelines is provided in the following paragraphs. Specific recommendations on which treatment to use are not provided since this was not the aim of European Code Against Cancer project; treatment depends on patient assessment and the recommendations in place in a specific country.
Chronic hepatitis B: available treatments.
The progression of HBV-related liver disease is associated with HBV DNA levels in the blood. Unlike HCV treatment, treatments against chronic hepatitis B can control but do not cure HBV infection, owing to the persistence of HBV in the hepatocyte genome. Antiviral therapy suppresses HBV replication, ensuring long-term suppression of the viral load. This is associated with histological improvement and reversal of fibrosis and cirrhosis, and thereby the likelihood of serious clinical disease is reduced [120] [121] [122] [123] .
Seven antiviral drugs falling into two groups are licensed in most European countries for treatment of chronic HBV infection: interferons (interferon alpha, INFa and pegylated (PEG)-INFa), and oral nucleos(t) ide analog (NA) polymerase inhibitors (lamivudine, adefovir, entecavir, telbivudine and tenofovir). PEG-INFa, entecavir, and tenofovir are licensed as first-line treatments and recommended as such in most current guidelines [117] .
Two SRs show that, compared to no treatment, INFa treatment significantly decreased the incidence of liver cirrhosis, liver cancer and liver-related death [124, 125] . However, in Jin's [125] , the effect on liver cancer is less significant when the Bayesian meta-analysis approach was used to combine data (RR 0.27, 95% CI 0.06, 1.03) compared to the Der Simonian-Laird approach (RR 0.47, 95% CI 0.26, 0.85). Compared to the first generation of NAs, development of resistance and relapse after treatment cessation seem to be significantly lower with entecavir and tenofovir [117, 126] . No direct evidence on the efficacy of entecavir/tenofovir in preventing or delaying HCC is available because these drugs are relatively new, and HCC development takes several decades. However, indirect evidence of cancer prevention is available, as reviewed recently [127, 128] .
Chronic hepatitis C treatment available or under
development. Successful eradication of HCV by treatment is defined as achievement of sustained virological response (SVR), i.e. absence of viremia 18 or 24 weeks after cessation of all antiviral medication, which is associated with a reduction of cirrhosis, incidence reduction of HCC and liver-related death [129] [130] [131] .
Since the introduction of indirect antiviral drugs, INFa monotherapy in 1990 and ribavirin (RBV) in combination with PEG-INFa in 2002, research has focused on developing more effective antiviral treatments that target HCV directly, are orally administered, safe and effective across all genotypes, and that achieve high SVR rates.
In 2011, telaprevir or boceprevir, the first generation of inhibitors of the HCV NS3/4A serine protease, were approved by regulatory agenciesthe US Food and Drug Administration (FDA), the EMA, and othersfor treatment of patients infected with chronic HCV genotype 1 in a triple-therapy regimen with RBV and INFa. This treatment has been reported to be more effective than the combination of RBV and PEG-INFa alone achieving a 60-70% SVR and a 75% reduced risk of HCC [132] . Unfortunately, this treatment is associated with more adverse events than the dual therapy, is expensive, requires several months' duration, and has a high pill burden.
Since 2011, a number of new antiviral compoundssuch as simeprevir, sofosbuvir and ledispasvirhas been developed, and some additional compounds are currently in various stages of development, including marketing authorization assessment. The main characteristics of these new products as reported in the literature are shorter treatment duration, easier administration protocol (i.e. a single daily oral administration), fewer side effects, and SVR rates of >90%. Simeprevir, a new generation of NS3/4A inhibitors, has been recently licensed as part of a combination treatment regimen with RBV and PEG-INFa. Evidence has shown that simeprevir is effective against HCV genotype 1 excluding the genotype 1a NS3 Q80K polymorphism [133] [134] [135] [136] [137] . Sofosbuvir, inhibitor of the HCV NS5B RNA polymerase, has recently been approved by the FDA and the EMA, and is effective and safe in combination with either RBV alone or with RBV and PEG-INFa for treatment of genotypes 1-6 [138] [139] [140] . Inhibitors of the HCV protein NS5A, such as ledipasvir, have recently been reviewed [141] and seem to be very promising new treatments. They are active against all HCV genotypes, require once-daily dosing, and show resistance profiles that do not overlap with those of other anti-HCV medicines. Marketing authorization application was made to the FDA and the EMA in February 2014 for a once-daily fixed-dose combination of ledipasvir with sofosbuvir [142, 143] . While the cost of new drugs is currently the major obstacle to their large-scale use, the manufacturing of these drugs is not per se expensive, opening the way to rapid price decline particularly in the public sector use [144] 3.2.2.3. Key points for the general public, healthcare providers and health policy makers. In the Q&A section [81] , based on the above evidence, the Working Group on Infections and Vaccination in the European Code Against Cancer project provided further information that would be of particular relevance for adults interested in learning more about what they could do to lower the risk of liver cancer from hepatitis B and C. Key messages include:
Individuals in high-risk groups for chronic HBV and/or HCV infection should consult their doctor or other healthcare provider to get a HBV or HCV test and be advised about treatment options, if tested positive. Effective treatments are available that will reduce the risk of developing liver cancer.
To prevent HCV transmission, individuals are advised to avoid injections and use oral treatments, when available and possible, especially when traveling to countries in which medical care is suboptimal. It is also recommended to avoid body piercing, tattooing or acupuncture, if there is any doubt about the safety/ hygiene of the procedure. Absence of proper needle handling is common in countries or regions outside Europe with limited economic resources and during times of political or social upheaval.
H. pylori
Role in cancer and situation in Europe
H. pylori was classified by the IARC Monographs Program as a Group 1 carcinogen in 1994; this classification was maintained in 2009 after more recent evidence was reviewed [3] . Approximately 89% of non-cardia gastric cancer cases, representing 78% of all gastric cancer cases worldwide, are now estimated to be attributable to chronic H. pylori infection [145] . Chronic H. pylori infection can also cause low-grade B-cell MALT gastric lymphoma, which is rare, representing less than 2% of all gastric cancers [3, 82] . Even if the recently observed decline in gastric cancer incidence rates is assumed to continue, the global burden in 2030 is expected to remain the same due to demographic change. Gastric cancer is the fifth most common malignancy in the world, but it is the third leading cause of death in both sexes, accounting for 8.8% of the total deaths from cancer worldwide in 2012. The highest mortality rates were reported in East Asia (ASMR of 24 and 9.8/100,000 for men and women, respectively) and the lowest in North America (2.8 and 1.5/100,000 for men and women, respectively) [18] .
In Europe, gastric cancer incidence varies by region: in 2012, the estimated ASIR was 11.7/100,000 (for men) and 5.9/100,000 (for women) in Southern Europe, 20.3 (men) and 8.9 (women) in Central and Eastern Europe, and 7.4 (men) and 3.7 (women) in Northern Europe [18] . H. pylori prevalence follows a similar pattern: prevalence of the infection was generally higher in countries in Southern Europe (e.g. 84.2%, 18-30 years of age, in Portugal [146] , 58.0%, 18-69 years of age, in Italy [147] ) and in Central and Eastern Europe (e.g. 61.7%, <17 years of age, in Bulgaria [148] ) than in Northern European countries (e.g. 11.0%, 25-50 years of age on average in Sweden [148] and 27.6%, 40-49 years of age in the UK [149] .
H. pylori infection is strongly associated with socioeconomic conditions [150] , and transmission appears to occur through close personal contact, particularly within the family [3] and typically in early childhood. Once established, infection usually persists throughout life unless it is treated. The prevalence of H. pylori infection has decreased in recent decades, particularly among children in developed countries, probably reflecting improvements in hygiene [151, 152] .
Intervention: H. pylori eradication
Several randomized trials conducted mainly in high-risk populations in Asia have produced evidence indicating that H. pylori eradication reduces the risk of developing gastric precancerous lesions and cancer [153] . In 2012, Ma and colleagues reported the long-term follow-up results of a randomized trial in H. pylori-seropositive adults drawn from a general population in China. By 15 years after randomization the OR of gastric cancer for H. pylori eradication was 0.61, 95% CI 0.38-0.96 [154] . A metaanalysis of six randomized trials estimated a relative risk of stomach cancer as 0.66 (95% CI 0.46-0.95) in asymptomatic infected individuals [155] .
There are treatments available containing combinations of antibiotics and acid-inhibitors taken for 7-14 days that can safely eradicate the infection in more than 80% of cases, depending on the antibiotic resistance patterns of H. pylori within the population [156] .
No screening program for systematically detecting and treating H. pylori is currently in place because important uncertainties regarding potential benefits and harms of such programs remain [157, 158] ; important questions inherent to the implementation of any screening programs (e.g. program costs, feasibility, appropriate target groups for intervention, and to the potential harm of mass therapy with antibiotics) must first be resolved before implementing large-scale programs. In Europe, important data are likely to emerge from RCTs that are currently in progress or about to begin in the region. An example is the Gastric Cancer Prevention Study by Predicting Atrophic Gastritis (GISTAR), which was launched in 2013 in Latvia to evaluate new intervention strategies for gastric cancer prevention in high-risk areas in East Europe.
Human immunodeficiency virus
Role in cancer and situation in Europe
The progression of disease related to human immunodeficiency virus (HIV) is well documented: acute infection stage, clinical latency, and AIDS (acquired immunodeficiency syndrome). AIDS is a life-threatening condition defined by severe immune dysfunction.
HIV-positive individuals have an increased cancer risk. Advanced-stage HIV disease is characterized by immunosuppression, which is a risk factor for many malignancies [82] . There are three AIDS-defining cancers: Kaposi sarcoma, NHL, and cervical cancer.
In contrast to the general population, a majority of lymphomas in HIV-infected people are caused by the Epstein-Barr virus [3] . HIVinfected persons also have elevated risks of other virus-related cancersnotably anal cancer, hepatocellular carcinoma, and Hodgkin lymphomaand a higher prevalence of lifestyleassociated risk factors, including smoking and alcohol consumption leading to increased risk of cancers of the head, neck and lung [3] . Overall, the risk of non-AIDS-defining cancers in HIV-infected people is double that of the general population [159] . Before the introduction of highly active antiretroviral therapy (HAART) in the mid-1990s, the life expectancy of people with HIV was severely compromised. However, the availability of HAART has led to a striking increase in survival.
At the end of 2011, it was estimated that around 900,000 people were living with HIV/AIDS in Western and Central Europe 1 with an estimated prevalence of 0.2% in adult population (15-49 years) [160] . The estimated prevalence in adults was generally higher in countries from Southern Europe (e.g. 0.7% in Portugal, 0.4% in Italy and Spain) than in other European countries (e.g. 0.3% in UK, 0.1% in Finland, Germany, Croatia, Czech Republic and Slovakia; and <0.1% in Croatia or Czech Republic) [160] .
A recent surveillance report prepared jointly by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe has pointed out that HIV infection is still a major public health issue in several countries in the EU/EEA. In 2013, 29,157 new HIV diagnoses were reported in EU/EEA countries, a rate of 5.7/100,000 population. The countries with the highest rates of new HIV cases were Estonia (24.6), Latvia (16.8) , Portugal (10.4), Belgium (10.0), Luxemburg (9.9) and the UK (9.4). The lowest rates were reported in Slovakia (1.5) and Croatia (2.0) [161] . There are no clear signs of overall decrease in HIV incidence due to continuing transmission in specific populations (Fig. 4) [161] . In 2013, in the EU/EEA region, the majority of new HIV diagnoses were men who have sex with men (42%) (MSM) followed by heterosexuals (33%), one third of those being migrants from countries or areas where there is a generalized HIV epidemic (i.e. sub-Saharan Africa) [161] . Transmission due to injecting drug use accounted for 5% of new HIV diagnoses, and transmission mode was unknown for nearly 20% of new diagnoses [161] .
The number of HIV diagnoses among MSM have increased by 33% since 2004 (Fig. 4b) [161] . When information on CD4 cell counts were reported by countries, nearly half (47%) of all newly infected individuals had a CD4 cell count <350/mm 3 , 27% of those being diagnosed with severe immunosuppression (CD4 <200/ mm 3 ) [161] . This population would have benefited from earlier HIV testing and HAART treatment (see below). 
The "test and treat" intervention
There is no vaccine to prevent HIV infection and no cure for chronic infection. Interventions provided to HIV-infected people include HAART treatment and counselling to reduce high-risk behaviors.
To evaluate HAART efficacy in preventing cancer in HIV-positive or AIDS patients, a systematic review was conducted, and 25 primary studies published after 2007 were selected (see Minozzi et al., 2015) . Of these, 19 are retrospective cohort studies comparing the pre-HAART to the HAART periods. The review showed that (1) the rate of AIDS-defining cancers (i.e. Kaposi sarcoma, NHL, and invasive cervical cancer) has continued to fall since the introduction of HAART, and (2) survival for NHL and Kaposi sarcoma has increased significantly. HAART prevents about two thirds of the cancersparticularly Kaposi sarcoma and NHLin HIV-infected persons [159] . For non-AIDS-defining cancers, the results are less clear and more conflicting: some studies found a significant increase in overall incidence after the introduction of HAART, whereas others found no significant differences between pre-HAART and HAART periods. The importance of preventing even moderate levels of HIV-induced immunosuppression is being increasingly appreciated, notably for the prevention of HPVassociated cancers [162] .
Recent SRs commissioned by the USPTF and WHO have shown that earlier treatment of HIV-positive individualsi.e. at CD4 count 500 cells/mm 3 , when individuals are more likely to be asymptomatic and detected by testingis associated with reduced risk for AIDS-related events or death and HIV transmission to uninfected sexual partners [163, 164] . Based on these results, both the USPTF and WHO issued recommendations in 2013 about testing (see below). More recently, in 2014, the US Department of Health and Human Services (HHS) recommended treatment for all HIV-infected individuals regardless of the patient's CD4 cell count. However, the strength of this HHS recommendation varies by patients' pre-treatment CD4 cell count, based on available scientific evidence; the recommendation is "strong" for CD4 count <500 cells/mm 3 , but "moderate" for CD4 count >500 cells/mm 3 [165, 166] .
On the basis of earlier treatment benefits, and the high percentage in the US (about 20-25%) of HIV-positive persons unaware of their positive status, the USPSTF has recommended HIV "screening" (in actual fact, voluntary testing) of all adolescents and adults aged 15-65 years at normal risk and younger adolescents and older adults at increased risk to identify asymptomatic but infected persons in US settings [167] (Fig. 5 ). In the absence of sufficient evidence to determine optimum time intervals for HIV testing, the USPSTF suggested that "one reasonable approach would be one-time screening of adolescent and adult patients to identify persons who are already HIV-positive, with repeated screening of those who are known to be at risk for HIV infection, those who are actively engaged in risky behaviors, and those who live in or receive medical care in a high-prevalence setting" (i.e. a geographic location or community with an HIV seroprevalence of at least 1% [167] ). It is worthy of note, however, that the USFTP recommend voluntary testing on the basis of risk assessment (see Fig. 5 "risk assessment") in settings where the prevalence of undiagnosed HIV infections 0.1% [167] . WHO also recommended HIV testing in asymptomatic individuals to initiate treatment in HIV-positive individuals at CD4 count 500 cells/mm 3 [164] . The population targeted by the WHO testing recommendation was defined on the basis of HIV prevalence; in low-prevalence HIV settings, i.e. <1% in the general population, WHO recommends (voluntary) HIV testing and counselling to "key populations that include both vulnerable and most-at-risk populations", and gives intervals for testing ( Table 2 ) [164] . In generalized HIV epidemics (i.e. HIV prevalence 1% in the general population) WHO recommends (voluntary) HIV testing and counselling to everybody.
Based on (a) the benefits of timely detection and treatment for cancer prevention, (b) recommendations for HIV testing in lowprevalence settings, and (c) figures obtained in the EU/EEA, the Working Group on Infections and Vaccination in the European Code Against Cancer project recommended that: in terms of HIVrelated cancers prevention, individuals in the groups most at risk for HIV infection and transmission in the EU/EEA (i.e. MSM, injection drugs users, and migrants from countries or settings with generalized HIV epidemics) but also individuals from other most at-risk populations (e.g. sex workers [164] ), should be aware of their HIV status and get treatment if needed. This is in accordance with the ECDC recommendation, which concluded in their 2014 report that "key populations are the cornerstones of HIV prevention in most EU/EEA countries" [161] . However, as there is no clear decrease in the trends of HIV transmission in the EU/EEA, with heterosexual transmission still remaining the second most common mode of HIV transmission, the Working Group also considered that it is important to extend the above recommendation to all individuals who are or have engaged in risky behaviors such as having unprotected sex or being injection drug users. Time intervals for HIV testing should be based on individual risk assessment and counselling.
Key point for the general public, healthcare providers and health policy makers.
In the Q&A section [81] , based on the above evidence, the Working Group on Infections and Vaccination in the European Code Against Cancer project provides additional information that would be of particular relevance for all adolescents and adults interested in learning more about what they could do to lower the risk of cancer from HIV infection. A key message is: Individuals most at risk for HIV infection are men who have sex with men, sex workers, injection drug users, people from a country with high rates of HIV (e.g. sub-Saharan Africa) or individuals who have unprotected sex without being sure that their partner is HIV-negative. Individuals most at risk should consult their healthcare provider to access counselling, testing, and, if the test is positive, to start treatment without delay. If the test is positive, delaying treatment allows the virus to spread in the body and damage the patient's health, in addition to increasing the risk of infecting sexual partners. If the test is negative, the healthcare provider will advise on whether repeated testing is needed based on the individual's HIV risk (see above). The tests used nowadays can usually tell whether a person has HIV within a month of infection. The most common tests require only a small amount of blood or saliva.
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Who to test
When to test Partners of people with HIV As soon after partner diagnosis as possible For the negative person in serodiscordant couples, offer re-testing every 6-12 months Families of index cases (adults and adolescents)
As soon as possible after the family member is diagnosed Key populations (adults and adolescents): people who inject drugs, men who have sex with men, transgender people and sex workers Table 5 .3 in "Summary of HIV testing and counselling recommendations for low-level and concentrated epidemics", World Health Organization, consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach (June 2013). a Low-level HIV epidemic: epidemics in which the prevalence of HIV infection has not consistently exceeded 1% in the general population nationally or 5% in any subpopulation; concentrated HIV epidemic: HIV has spread rapidly in one or more defined subpopulations but is not well established in the general population. Numerical proxy: HIV prevalence is consistently over 5% in at least one defined subpopulation but is less than 1% among pregnant women in urban areas.
